펩타이드 약물 복합체 시장 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 지역별, 부문별 예측(2025-2030년)

Peptide Drug Conjugates Market Size, Share & Trends Analysis Report By Product (Illuccix, Pluvicto, CBX-12, Pipeline Products), By Type (Diagnostic, Therapeutic), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,163,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,536,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,280,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

펩타이드 약물 복합체 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 펩타이드 약물 복합체 세계 시장 규모는 2030년까지 128억 4,000만 달러에 달할 것으로 추정되며, 2025-2030년 동안 19.21%의 CAGR로 성장할 것으로 예상됩니다.

시장 성장의 배경에는 전 세계 암 환자의 급증과 그에 따른 사망률, 펩타이드 약물 복합체(PDC)의 강력한 임상 검사 파이프라인, 저분자 화학요법제와 관련된 통제할 수 없는 독성 등 기존 제품의 관련 부작용이 있습니다.

세계보건기구(WHO)에 따르면, 암은 전 세계 질병 관련 사망의 주요 원인으로, 2020년에는 전 세계적으로 약 1,000만 명, 미국에서는 600만 명 이상이 암으로 사망했습니다. 또한, cancer.gov에 따르면 2040년까지 연간 신규 암 환자 수는 2,900만 명, 암 관련 사망자 수는 1,600만 명에 달할 것으로 추정됩니다. 따라서, 통제되지 않은 세포 증식을 표적으로 하는 PDC와 같은 새로운 치료법에 대한 수요 증가는 펩타이드 약물 복합체 시장의 성장을 촉진할 것으로 예상됩니다.

현재 Lutathera(Lu 177 dotatate)와 Pepaxto(Melflufen)는 FDA가 통제되지 않은 세포 증식을 치료하기 위해 승인한 두 가지 PDC입니다. 성인 소마토스타틴 수용체 양성 위장췌장 신경내분비종양을 적응증으로 하는 노바티스의 루타세라(루테튬 Lu 177)가 FDA의 승인을 받은 PDC가 있습니다. 이후 2021년 2월 Oncopeptides ABs는 다발성 골수종 치료제로 Pepaxto(멜파란)의 FDA 조기 승인을 받았다고 발표했습니다. 이 분야는 PDC가 제한적으로 존재하기 때문에 성장에 유리한 기회가 있습니다.

또한, 탄탄한 임상시험 파이프라인과 신규 PDC의 출시가 예상되어 예측 기간 동안 시장 성장을 견인할 것으로 보입니다. 뇌종양을 대상으로 임상 3상 중인 PDC ANG1005, 폐암을 대상으로 임상 2상 중인 PDC BT5528과 BT1718, 소세포폐암을 적응증으로 하는 임상 2상 PDC 후보물질인 CBX-12 등이 그 배경입니다.

주요 기업들은 금융 투자와 함께 공동 연구, M&A, 계약과 같은 전략적 이니셔티브를 수행하고 있으며, 이는 시장 성장을 촉진하고 있습니다. 예를 들어, 2021년 12월 Coherent Biopharma와 WuXi STA는 펩타이드 약물 복합체를 포함한 현재와 미래의 치료법을 개발하기 위한 전략적 파트너십 계약을 발표했습니다.

펩타이드 약물 복합체 시장 보고서 하이라이트

• 2024년에는 치료 부문이 산업을 지배하고 가장 빠른 성장을 보였습니다.
• 풀빅 부문은 2024년 42.52%의 매출 점유율로 업계를 지배했으며, 예측 기간 동안 가장 빠른 CAGR을 보일 것으로 예상됩니다.
• 북미 펩타이드 약물 복합체 시장은 2024년 세계 점유율의 75.02%를 차지하며 선두를 차지했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 펩타이드 약물 복합체 시장 변수, 동향, 범위

• 상부 시장 전망
• 보조 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 도파민 작용제 분석 툴
  • Porters 분석
  • PESTEL 분석
• 파이프라인 분석
  • 단계 1
  • 단계 2
  • 단계 3

제4장 펩타이드 약물 복합체 시장 : 제품별, 추정·동향 분석

• 펩타이드 약물 복합체 시장 : 제품 부문 대시보드
• 펩타이드 약물 복합체 시장 : 제품 변동 분석, 2024년과 2030년
• Illuccix
• Pluvicto
• Lutathera
• OctreoScan
• 기타

제5장 펩타이드 약물 복합체 시장 : 유형별, 추정·동향 분석

• 펩타이드 약물 복합체 시장 : 유형 부문 대시보드
• 펩타이드 약물 복합체 시장 : 유형 변동 분석, 2024년과 2030년
• 치료
• 진단

제6장 펩타이드 약물 복합체 시장 : 지역별, 추정·동향 분석

• 펩타이드 약물 복합체 시장 점유율, 지역별, 2024년과 2030년, 100만 달러
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 진출 기업의 최근 동향과 영향 분석
• 기업 분류
• 참여자 개요
• 제품 벤치마크
• 기업 시장 점유율 분석, 2024년
• 기업 개요
  • Novartis AG
  • AstraZeneca
  • Oncopeptides AB
  • Bicycle Therapeutics
  • Cybrexa
  • Angiochem Inc.
  • Soricimed Biopharma
  • Theratechnologies Inc.

제8장 결론

ksm

영문 목차

영문목차

Peptide Drug Conjugates Market Growth & Trends:

The global peptide drug conjugates market size is estimated to reach USD 12.84 billion by 2030, registering to grow at a CAGR of 19.21% from 2025 to 2030 according to a new report by Grand View Research, Inc. The growth of market is attributed to the global upsurge in cancer cases and related mortality, strong clinical trial pipeline with peptide drug conjugates (PDCs) and associated side effects of the existing products such as uncontrolled toxicity associated with small molecule chemotherapeutic agents.

According to WHO, cancer is the leading cause of disease related deaths, worldwide. In 2020, around 10.0 million deaths globally and more than 6.0 million deaths in the U.S. were recorded due to the cancer. Furthermore, as per cancer.gov, by 2040, the new cancer cases patients per year is estimated to reach to 29.0 million and the number of cancer-related deaths to 16.0 million. Therefore, rising demand for the novel treatment like PDCs to target uncontrolled cell growth is expected to fuel the peptide drug conjugates market growth.

Currently, Lutathera (Lu 177 dotatate) and Pepaxto (Melflufen) are the two FDA approved PDCs to treat uncontrolled cell growth. The marketplace has the FDA approved PDC as the Novartis's Lutathera (lutetium Lu 177)indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults. Later, in February 2021, Oncopeptides ABs announced the FDA's accelerated approval for Pepaxto (Melphalan) indicated for the treatment in multiple myeloma. Presence of limited PDCs in space in offering remunerative opportunity for the growth.

Furthermore, presence of robust clinical trial pipeline and expected launch of new PDCs is anticipated to boost the market growth during the forecast period. These can attribute due to the PDC ANG1005 under phase 3 clinical studies for brain tumor, and PDCs BT5528 and BT1718 under phase 2 to clinical studies for lung cancer. CBX-12 is another phase 2 PDC candidate indicated for the small cell lung cancer treatment.

Key players are undertaking strategic initiatives such as collaborations, merger & acquisitions, agreements, along with financial investments, which is driving the market growth. For instance, in December 2021, Coherent Biopharma and WuXi STA announced the strategic partnership agreement to develop their current and future therapeutic drugs including peptide drug conjugates.

Peptide Drug Conjugates Market Report Highlights:

• The therapeutic segment dominated the industry in 2024 and is anticipated to witness the fastest growth.
• The pluvicto segment dominated the industry with a revenue share of 42.52% in 2024 and is expected to exhibit the fastest CAGR over the forecast period.
• North America peptide drug conjugates market held a leading position in 2024, accounting for 75.02% of the global share.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Peptide Drug Conjugates Market Variables, Trends, & Scope

• 3.1. Parent Market Outlook
• 3.2. Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market drivers analysis
    • 3.3.1.1. Rising prevalence of neurological disorders increasing disease prevalence
    • 3.3.1.2. Robust clinical trial pipeline
    • 3.3.1.3. Growing focus on targeted drug delivery
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Long R&D time and slow clinical development process
    • 3.3.2.2. Stringent regulations associated with peptide drug conjugates (PDC's)
• 3.4. Dopamine Agonist Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape
• 3.5. Pipeline Analysis
  • 3.5.1. Phase 1
  • 3.5.2. Phase 2
  • 3.5.3. Phase 3

Chapter 4. Peptide Drug Conjugates Market: By Product Estimates & Trend Analysis

• 4.1. Peptide Drug Conjugates Market: Product Segment Dashboard
• 4.2. Peptide Drug Conjugates Market: By Product Movement Analysis, 2024 & 2030 (USD Million)
• 4.3. Illuccix
  • 4.3.1. Illuccix Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Pluvicto
  • 4.4.1. Pluvicto Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Lutathera
  • 4.5.1. Lutathera Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. OctreoScan
  • 4.6.1. OctreoScan Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Peptide Drug Conjugates Market: Type Estimates & Trend Analysis

• 5.1. Peptide Drug Conjugates Market: Type Segment Dashboard
• 5.2. Peptide Drug Conjugates Market: By Type Movement Analysis, 2024 & 2030 (USD Million)
• 5.3. Therapeutics
  • 5.3.1. Therapeutics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Diagnostics
  • 5.4.1. Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Peptide Drug Conjugates Market: Regional Estimates & Trend Analysis

• 6.1. Peptide Drug Conjugates Market Share, By Region, 2024 & 2030, USD Million
• 6.2. North America
  • 6.2.1. North America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.2. U.S.
    • 6.2.2.1. Key Country Dynamics
    • 6.2.2.2. Target Disease Prevalence
    • 6.2.2.3. Regulatory Framework
    • 6.2.2.4. Reimbursement Framework
    • 6.2.2.5. U.S. Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.3. Canada
    • 6.2.3.1. Key Country Dynamics
    • 6.2.3.2. Target Disease Prevalence
    • 6.2.3.3. Regulatory Framework
    • 6.2.3.4. Reimbursement Framework
    • 6.2.3.5. Canada Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.2.4. Mexico
    • 6.2.4.1. Key Country Dynamics
    • 6.2.4.2. Target Disease Prevalence
    • 6.2.4.3. Regulatory Framework
    • 6.2.4.4. Reimbursement Framework
    • 6.2.4.5. Mexico Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.3. Europe
  • 6.3.1. Europe Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.2. UK
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Target Disease Prevalence
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. Reimbursement Framework
    • 6.3.2.5. Uk Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.3. Germany
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Target Disease Prevalence
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. Reimbursement Framework
    • 6.3.3.5. Germany Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.4. France
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Target Disease Prevalence
    • 6.3.4.3. Regulatory Framework
    • 6.3.4.4. Reimbursement Framework
    • 6.3.4.5. France Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.5. Italy
    • 6.3.5.1. Key Country Dynamics
    • 6.3.5.2. Target Disease Prevalence
    • 6.3.5.3. Regulatory Framework
    • 6.3.5.4. Reimbursement Framework
    • 6.3.5.5. Italy Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.6. Spain
    • 6.3.6.1. Key Country Dynamics
    • 6.3.6.2. Target Disease Prevalence
    • 6.3.6.3. Regulatory Framework
    • 6.3.6.4. Reimbursement Framework
    • 6.3.6.5. Spain Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.7. Denmark
    • 6.3.7.1. Key Country Dynamics
    • 6.3.7.2. Target Disease Prevalence
    • 6.3.7.3. Regulatory Framework
    • 6.3.7.4. Reimbursement Framework
    • 6.3.7.5. Denmark Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.8. Sweden
    • 6.3.8.1. Key Country Dynamics
    • 6.3.8.2. Target Disease Prevalence
    • 6.3.8.3. Regulatory Framework
    • 6.3.8.4. Reimbursement Framework
    • 6.3.8.5. Sweden Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3.9. Norway
    • 6.3.9.1. Key Country Dynamics
    • 6.3.9.2. Target Disease Prevalence
    • 6.3.9.3. Regulatory Framework
    • 6.3.9.4. Reimbursement Framework
    • 6.3.9.5. Norway Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Asia Pacific
  • 6.4.1. Asia Pacific Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. Japan
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. Japan Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. China
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. China Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. India
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. India Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.5. Australia
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Target Disease Prevalence
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. Reimbursement Framework
    • 6.4.5.5. Australia Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.6. South Korea
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Target Disease Prevalence
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Reimbursement Framework
    • 6.4.6.5. South Korea Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.7. Thailand
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Target Disease Prevalence
    • 6.4.7.3. Regulatory Framework
    • 6.4.7.4. Reimbursement Framework
    • 6.4.7.5. Thailand Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Latin America
  • 6.5.1. Latin America Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. Brazil
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. Japan Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Argentina
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. China Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Middle East and Africa
  • 6.6.1. Middle East and Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. South Africa
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. South Africa Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. Saudi Arabia
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. Saudi Arabia Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. UAE
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. UAE Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Kuwait
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Kuwait Peptide Drug Conjugates Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Participant Overview
• 7.4. Financial Performance
• 7.5. Product Bench Marking
• 7.6. Company Market Share Analysis, 2024
• 7.7. Company Profiles
  • 7.7.1. Novartis AG
    • 7.7.1.1. Participant's Overview
    • 7.7.1.2. Financial Performance
    • 7.7.1.3. Product Benchmarking
    • 7.7.1.4. Recent Developments/ Strategic Initiatives
  • 7.7.2. AstraZeneca
    • 7.7.2.1. Participant's Overview
    • 7.7.2.2. Financial Performance
    • 7.7.2.3. Product Benchmarking
    • 7.7.2.4. Recent Developments/ Strategic Initiatives
  • 7.7.3. Oncopeptides AB
    • 7.7.3.1. Participant's Overview
    • 7.7.3.2. Financial Performance
    • 7.7.3.3. Product Benchmarking
    • 7.7.3.4. Recent Developments/ Strategic Initiatives
  • 7.7.4. Bicycle Therapeutics
    • 7.7.4.1. Participant's Overview
    • 7.7.4.2. Financial Performance
    • 7.7.4.3. Product Benchmarking
    • 7.7.4.4. Recent Developments/ Strategic Initiatives
  • 7.7.5. Cybrexa
    • 7.7.5.1. Participant's Overview
    • 7.7.5.2. Financial Performance
    • 7.7.5.3. Product Benchmarking
    • 7.7.5.4. Recent Developments/ Strategic Initiatives
  • 7.7.6. Angiochem Inc.
    • 7.7.6.1. Participant's Overview
    • 7.7.6.2. Financial Performance
    • 7.7.6.3. Product Benchmarking
    • 7.7.6.4. Recent Developments/ Strategic Initiatives
  • 7.7.7. Soricimed Biopharma
    • 7.7.7.1. Participant's Overview
    • 7.7.7.2. Financial Performance
    • 7.7.7.3. Product Benchmarking
    • 7.7.7.4. Recent Developments/ Strategic Initiatives
  • 7.7.8. Theratechnologies Inc.
    • 7.7.8.1. Participant's Overview
    • 7.7.8.2. Financial Performance
    • 7.7.8.3. Product Benchmarking
    • 7.7.8.4. Recent Developments/ Strategic Initiatives

Chapter 8. Conclusion

관련자료